Evozyne is a biotechnology company that is developing a new class of protein therapeutics. The company's platform uses computational protein design to create novel proteins that can be used to treat a variety of diseases, including cancer, autoimmune disorders, and genetic diseases. Evozyne was founded in 2016 and is headquartered in Oxford, England.